Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 4Thoracic 3Sarcoma 3Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × DOXO-EMCH × Thoracic × Clear all
NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

ImmunityBio, Inc.

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02200757 2024-06-25

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

ImmunityBio, Inc.

Phase 2 Completed
135 enrolled 11 charts
Thoracic

Small Cell Lung Carcinoma

NCT00472771 2012-02-09

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

CytRx

Phase 2 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡